SmithKline

GlaxoSmithKline honors healthcare nonprofits with $40,000 IMPACT Awards

Friday, November 9, 2012 02:02 PM

GlaxoSmithKline has announced five recipients of its annual GlaxoSmithKline IMPACT Awards. In total, the North Carolina and Philadelphia-area healthcare nonprofit organizations will receive $200,000 in grant funding ($40,000 each) for providing access to healthcare for the underserved in their communities.

More... »

CEO of Sanofi designated as new president elect of EFPIA

Wednesday, November 7, 2012 01:55 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the pharmaceutical industry operating in Europe, has designated Christopher A. Viehbacher, CEO of Sanofi, as the new president elect of EFPIA. He will take up the position as of June 2013 for a two year term.

More... »

Vertex, GSK partner on phase II all-oral study of VX-135, GSK2336805 for Hep C

Friday, November 2, 2012 11:23 AM

Vertex Pharmaceuticals, a global biotechnology company based in Cambridge, Mass., has entered into a non-exclusive agreement with GlaxoSmithKline (GSK) to conduct a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex's nucleotide analogue HCV polymerase inhibitor VX-135 and GSK's NS5A inhibitor GSK2336805.

More... »

Shionogi, ViiV Healthcare to commercialize and develop integrase inhibitor portfolio

Tuesday, October 30, 2012 11:19 AM

ViiV Healthcare, a global specialist HIV company based in the U.K., and Shionogi, a Japanese research-driven pharmaceutical company, have entered into an agreement substantially revising their integrase inhibitor relationship.

More... »

Thrasos secures $35M for THR-184 phase II program for acute kidney injury

Friday, October 26, 2012 11:39 AM

Thrasos Therapeutics, a Canadian clinical stage biotherapeutics company, has completed a $35 million financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI).

More... »

GSK announces initiatives to advance openness and collaboration for global health challenges

Friday, October 12, 2012 11:04 AM

Global healthcare company GlaxoSmithKline has announced new measures to further advance its commitment towards greater openness, transparency and collaboration, designed to help develop new solutions for the world’s most serious health challenges.

More... »

Aeras, GSK to jointly advance TB vaccine

Wednesday, October 10, 2012 11:56 AM

Aeras, a fully-integrated tuberculosis (TB) vaccine development organization, has signed an agreement with global healthcare company GlaxoSmithKline to jointly advance the clinical development of an investigational TB vaccine containing GSK's proprietary M72 antigen and AS01E adjuvant. 

More... »

Epizyme earns $4M in milestones from GSK for novel HMT therapeutics

Thursday, October 4, 2012 11:52 AM

Epizyme, a pharmaceutical company focused personalized therapeutics for cancer, received a $4 million milestone payments from collaborator GlaxoSmithKline based on the achievement of pre-clinical milestones.

More... »

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

DART Therapeutics appoints executive team

Friday, September 14, 2012 01:51 PM

DART Therapeutics, a Cambridge, Mass.-based new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has appointed an executive team. Members include co-founder and executive chairman Eugene W. Williams with the new title of CEO, Ernest D. Bush, PhD, as chief scientific officer., Dr. Elliot Goldstein as chief medical officer, and Cabot Brown as chief financial officer.

More... »